Celldex discontinues late-stage study of brain cancer vaccine
Celldex Therapeutics Inc said it would discontinue a late-stage study of its brain cancer vaccine after an independent interim analysis suggested the therapy might not show a statistically significant difference in survival rates compared with chemotherapy.
The company's shares plummeted about 60 percent to $3.28 in premarket trading on Monday.
The vaccine, Rintega, is designed to target a specific genetic mutation seen in about 30 percent of glioblastoma multiforme (GBM) tumors.
After a preplanned interim analysis, the independent data safety and monitoring board estimated that overall survival of patients with newly-diagnosed GBM who were given Rintega was at a par with those in the control group.
Based on the board's recommendation, Celldex is abandoning the study, it said, adding that it did not expect to incur substantial additional costs related to Rintega.
The company's shares plummeted about 60 percent to $3.28 in premarket trading on Monday.
The vaccine, Rintega, is designed to target a specific genetic mutation seen in about 30 percent of glioblastoma multiforme (GBM) tumors.
After a preplanned interim analysis, the independent data safety and monitoring board estimated that overall survival of patients with newly-diagnosed GBM who were given Rintega was at a par with those in the control group.
Based on the board's recommendation, Celldex is abandoning the study, it said, adding that it did not expect to incur substantial additional costs related to Rintega.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.